First-Line Systemic Therapy for Metastatic Clear-Cell Renal Cell Carcinoma: Critical Appraisal of Emerging Options.
Until recently, a dichotomy existed in the front-line approach of metastatic clear-cell renal cell carcinoma (mRCC). Specifically, patients received either targeted therapy or immunotherapy. Targeted therapy entailed use of agents blocking signaling through the vascular endothelial growth factor (VE...
| Publicado en: | Targeted Oncology Vol. 14; no. 6; pp. 639 - 646 |
|---|---|
| Autores principales: | , , , , |
| Formato: | review Journal Article |
| Publicado: |
Springer Nature
Dec2019
|
| Acceso en línea: | Ver este registro en EBSCOhost |